Suppr超能文献

淋巴管浸润和脉管浸润对浸润性乳腺癌的预后意义。

The prognostic significance of lymphovascular invasion in invasive breast carcinoma.

机构信息

Department of Histopathology, Nottingham University Hospitals National Health Service Trust, Nottingham, United Kingdom.

出版信息

Cancer. 2012 Aug 1;118(15):3670-80. doi: 10.1002/cncr.26711. Epub 2011 Dec 16.

Abstract

BACKGROUND

Although lymphovascular invasion (LVI) has been associated with a poor outcome in patients with breast cancer, it is not included in most internationally recognized staging systems, including the American Joint Committee on Cancer tumor, lymph node, metastasis (TNM) classification. This is mainly because it remains unclear whether the presence of LVI is an independent, high-risk criterion in clinically relevant staging subgroups.

METHODS

The current study was based on a large and well characterized consecutive series of patients who had operable (pathologic T1 [pT1]-pT2, pathologic N0 [pN0]-pN3, M0) breast cancer (3812 informative cases) who were treated according to standard protocols at a single institution and who had long-term follow-up to assess the prognostic value of definite LVI in clinically and molecularly relevant staging subgroups.

RESULTS

LVI was strongly associated with both breast cancer-specific survival (BCSS) and distant metastasis-free survival (DMFS) in the entire series and in different subgroups. Multivariate analyses identified LVI as an independent predictor of both BCSS and DMFS in patients with operable breast cancer overall; in the TNM clinical subgroups pT1a-pT1c/pN0 and pT2/pN0; and in the molecular classes estrogen receptor (ER)-positive, ER-negative, human epidermal growth factor 2 [HER2]-negative, and triple-negative. In patients who had lymph node-negative tumors, LVI could be used as a high-risk criterion providing survival disadvantage equivalent to that provided by 1 or 2 involved lymph nodes (pN0 to pN1) and to that provided by 1 size category (pT1 to pT2). The use of immunohistochemistry for detecting an endothelial-specific marker contributed to the prognostic significance of LVI when applied to routine LVI negative/possible cases.

CONCLUSIONS

LVI provided a strong predictor of outcome in patients with invasive breast cancer and should be incorporated into breast cancer staging systems.

摘要

背景

尽管脉管侵犯(LVI)与乳腺癌患者的不良预后相关,但它并未包含在大多数国际公认的分期系统中,包括美国癌症联合委员会的肿瘤、淋巴结、转移(TNM)分类。这主要是因为目前尚不清楚 LVI 的存在是否是临床相关分期亚组中独立的高危标准。

方法

本研究基于一个大型且特征明确的连续系列患者,这些患者患有可手术(病理 T1[pT1]-pT2、病理 N0[pN0]-pN3、M0)乳腺癌,根据单一机构的标准方案进行治疗,并进行长期随访以评估明确的 LVI 在临床和分子相关分期亚组中的预后价值。

结果

LVI 与整个系列以及不同亚组中的乳腺癌特异性生存(BCSS)和远处无转移生存(DMFS)均密切相关。多变量分析确定 LVI 是可手术乳腺癌患者整体 BCSS 和 DMFS 的独立预测因子;在 TNM 临床亚组 pT1a-pT1c/pN0 和 pT2/pN0 中;以及在雌激素受体(ER)阳性、ER 阴性、人表皮生长因子 2 [HER2]阴性和三阴性的分子类别中。在淋巴结阴性肿瘤患者中,LVI 可作为高风险标准,提供与 1 个或 2 个受累淋巴结(pN0 至 pN1)和 1 个大小类别(pT1 至 pT2)提供的生存劣势相当的生存劣势。当应用于常规 LVI 阴性/可能病例时,使用免疫组织化学检测内皮特异性标志物可提高 LVI 的预后意义。

结论

LVI 为浸润性乳腺癌患者的预后提供了强有力的预测指标,应纳入乳腺癌分期系统。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验